GEN-MKT-18-7897-A
Feb 17, 2016 | Blogs, Food / Beverage | 0 comments
During RAFA 2015, New Food Magazine hosted a roundtable (sponsored by SCIEX) to bring together experts with routine food testing backgrounds to discuss the latest industry trends, challenges, recent technological advances, and expectations of future laboratories.
Both Vincent Paez, Senior Director of Food Testing and Andre Schreiber, Technical Applications Manager from SCIEX were in attendance and contribute with their extensive experience of working with and supporting routine testing laboratories, as well as developing advanced workflows on the forefront of food safety.
The roundtable began with a simple question, “In the next 10 years what key changes do you see happening in the food and beverage industry in terms of food analysis?” A detailed discussion followed which covered the aspects of commercial laboratory testing, university laboratory research, the rise of digital technologies and the simplification of processes – in particular, the importance of informatics.
If you are interested in learning more about what each of the speakers had to say we have embedded the full 51-minute roundtable for you to watch below.
Be sure to leave a comment below and share your thoughts on the questions asked as part of the discussion, or raise any questions you would like to be included in future roundtables!
Also, if you’re interested in watching more from RAFA 2015, check out Andre’s seminar titled “Igniting Your Routine Testing Methods.”
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network